Indication
Gastrointestinal Stromal Tumor
10 clinical trials
13 products
3 drugs
Clinical trial
Real-World Regorafenib Use Among Advanced Gastrointestinal Stromal TumorsStatus: Not yet recruiting, Estimated PCD: 2024-04-28
Product
RegorafenibProduct
HQP1351Clinical trial
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]Status: Recruiting, Estimated PCD: 2026-04-24
Product
IDRX-42Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Status: Active (not recruiting), Estimated PCD: 2023-11-16
Product
RepaglinideProduct
RipretinibProduct
BelzutifanClinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsStatus: Recruiting, Estimated PCD: 2027-02-26
Clinical trial
A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer TherapiesStatus: Completed, Estimated PCD: 2022-07-20
Product
SunitinibClinical trial
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
MEK162Product
Imatinib MesylateClinical trial
Advanced Gastrointestinal Endoscopic ImagingStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Fluorescent PeptideProduct
fluoresceinProduct
Indocyanine GreenClinical trial
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable SarcomaStatus: Completed, Estimated PCD: 2019-04-01
Product
IpilimumabDrug
T-VECClinical trial
A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Status: Active (not recruiting), Estimated PCD: 2023-12-31
Drug
RegorafenibDrug
imatinib